Shares of AbbVie Inc. ABBV slid 3.14% to $174.20 Thursday, on what proved to be an all-around dismal trading session for the ...

Investing isn’t easy, and given the current market volatility, retail investors are on edge, worrying about their portfolios.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

A significant trading signal occurred for AbbVie stock at $164.86, ahead of tariff reversal news. ABBV climbed up to 9.2% ...

Goldman Sachs reaffirmed its "neutral" rating on AbbVie with a target price of $194, indicating mild optimism without fanfare. Six analysts say “hold,” eighteen say “buy,” and three shout “strong buy” ...

Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on AbbVie (ABBV) to $241 from $239 and keeps an Overweight rating on the ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

Pharma tariffs could crush wages, sparking an HR crisis. How the US drug import tax and US pharma levies hit your workforce ...

The European Commission (EC) has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg ...